K. Atsou

发表

Network meta-analysis of immune-oncology monotherapy as first-line treatment for advanced non-small-cell lung cancer in patients with PD-L1 expression ⩾50%

N. Freemantle, P. Guyot, G. Gullo, 2022, Therapeutic advances in medical oncology.

Simulation-Based Estimates of the Effectiveness and Cost-Effectiveness of Pulmonary Rehabilitation in Patients with Chronic Obstructive Pulmonary Disease in France

G. Hejblum, C. Chouaid, P. Créquit, 2016, PloS one.

Cost-Effectiveness of Cemiplimab Versus Standard of Care in the United States for First-Line Treatment of Advanced Non-small Cell Lung Cancer With Programmed Death-Ligand 1 Expression ≥50.

P. Guyot, F. Wilson, C. Smare, 2021, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

The Chikungunya Epidemic on La Réunion Island in 2005–2006: A Cost-of-Illness Study

A. Flahault, Y. Yazdanpanah, P. Boelle, 2011, PLoS neglected tropical diseases.

Assessing the Value of Cemiplimab for Adults With Advanced Cutaneous Squamous Cell Carcinoma: A Cost-Effectiveness Analysis.

D. Ayers, N. Khushalani, S. Keeping, 2021, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

Cost-utility evaluation of vortioxetine in patients with Major Depressive Disorder experiencing inadequate response to alternative antidepressants in the United Kingdom.

A. Young, N. Danchenko, S. Cure, 2017, Journal of affective disorders.

Simulation-Based Estimates of Effectiveness and Cost-Effectiveness of Smoking Cessation in Patients with Chronic Obstructive Pulmonary Disease

G. Hejblum, C. Chouaid, K. Atsou, 2011, PloS one.

Variability of the chronic obstructive pulmonary disease key epidemiological data in Europe: systematic review

G. Hejblum, C. Chouaid, K. Atsou, 2011, BMC medicine.

Cost-benefit analysis of a simulated institution-based preoperative smoking cessation intervention in patients undergoing total hip and knee arthroplasties in France.

B. Dautzenberg, G. Hejblum, C. Chouaid, 2009, Chest.

Cost-effectiveness of vortioxetine compared with levomilnacipran and vilazodone in patients with major depressive disorder switching from an initial antidepressant

L. Ereshefsky, C. François, N. Danchenko, 2020, Expert review of pharmacoeconomics & outcomes research.

Cost-effectiveness analysis of cemiplimab vs pembrolizumab for treatment of advanced cutaneous squamous cell carcinoma

D. Ayers, P. Guyot, S. Keeping, 2021, Journal of managed care & specialty pharmacy.

Cost-utility evaluation of vortioxetine in patients with Major Depressive Disorder experiencing inadequate response to alternative antidepressants in the United Kingdom.

S. Cure, R. Campbell, M. Brignone, 2017, Journal of affective disorders.